# T1D Blood Sugar Prediction App — Competitive Landscape & Strategic Update
*Prepared: March 29, 2026 | Rob Lobster 🦞*

## 🚨 MAJOR DEVELOPMENT: Dexcom + Oura Partnership

This changes the game for Joe's app thesis. Here's what happened:

### The Partnership (Announced 2024, Launched June 2025)
- **Dexcom invested $75 million in Oura** — this is not a casual integration
- **Stelo Glucose Biosensor** by Dexcom now integrates directly into the Oura App
- Oura launched **"Metabolic Health"** features combining:
  - Glucose monitoring (via Stelo CGM)
  - Sleep, stress, HRV, and activity data (via Oura Ring)
  - AI-powered meal analysis (photo-based)
  - **Exactly the stress-glucose correlation Joe's app was designed to surface**

### What This Means for Joe's App
**The good news:** This validates the thesis completely. Dexcom and Oura together proved that stress/sleep/activity data paired with glucose monitoring is commercially viable. A $75M investment says the market is real.

**The challenge:** Oura + Dexcom are now doing a version of what Joe envisioned, but:
- They're approaching it as a **general wellness** play (not T1D-specific)
- Stelo is positioned for non-insulin users and general metabolic health — NOT for Type 1 diabetics who need Dexcom G7
- They track correlations but **don't predict** — they show you what happened, not what's coming
- No cortisol-specific stress pathway (they use HRV as a proxy, not direct cortisol)

### Joe's Differentiation Path (Still Viable)
1. **Prediction, not just monitoring** — "Predict, not medicate" remains unique
2. **T1D-specific** — Oura/Stelo targets general wellness; T1D patients need insulin dosing support
3. **Dexcom G7 + Oura Ring 4** pairing — use Terra API to pull from both (Oura's API gives HRV, stress scores; Dexcom's gives real-time glucose)
4. **Claude AI integration** for personalized pattern recognition and alerts
5. **Caregiver alerts** — predict a crash/spike and notify the partner (Keli could be the first test case)

---

## Competitive Map: Top 10 T1D Apps (2026)

| App | Focus | CGM Integration | Stress/HRV | Prediction | Rating |
|-----|-------|----------------|------------|------------|--------|
| **Gluroo** | Family sharing, data sync | Dexcom, Libre, Omnipod | ❌ | ❌ | 4.7/4.6 |
| **Glucose Buddy** | All-in-one tracking | Dexcom, Apple Health | ❌ | ❌ | 4.8/4.0 |
| **mySugr** | T1D gamified logging | CGM sync | ❌ | ❌ | 4.6/4.5 |
| **Diabetes:M** | Data-heavy analysis | Apple Watch, CGM | ❌ | ❌ | High |
| **Health2Sync** | Global, coaching | Multiple | ❌ | ❌ | High |
| **UndermyFork** | Food-glucose correlation | Dexcom cloud | ❌ | ❌ | 4.6 |
| **Oura + Stelo** | Metabolic health | Stelo by Dexcom | ✅ (HRV) | ❌ | N/A |
| **Sugarmate** | Dexcom companion | Dexcom | ❌ | ❌ | High |
| **Tidepool** | Open-source data platform | Multiple CGMs/pumps | ❌ | ❌ | N/A |
| **Joe's T1D App** | Stress→glucose prediction | Dexcom G7 + Oura/wearables | ✅ (HRV+stress) | ✅ | TBD |

### Key Takeaway: NOBODY IS DOING PREDICTION

Every single app on the market is **retrospective** — they show you what happened. Joe's app thesis is the only one focused on **prospective prediction** using stress signals to anticipate glucose events BEFORE they happen.

---

## Emerging Technology Threats & Opportunities

### Next-Gen CGMs (Coming 2026-2028)
1. **Glucotrack** — completely non-invasive (ultrasound-based), pivotal trial 2026, possible launch 2028
2. **FreeStyle Libre 3** — AI-powered food insights ("Libre Assist"), photo-to-carb analysis
3. **Medtronic Simplera Sync** — FDA submission by April 2026
4. **Continuous Ketone Monitors (CKMs)** — new category for DKA detection

### Academic Research Validating the Thesis
- **Springer Nature (2025):** Review of noninvasive wearable biosensors explicitly discusses simultaneous detection of glucose, cortisol, and HRV for "personalized diabetes management"
- **Science Advances (2025):** "Stressomic" — wearable microfluidic biosensor for real-time stress hormone profiling (cortisol, DHEA, norepinephrine)
- **MDPI Sensors (2025):** "Development of Non-Invasive Continuous Glucose Prediction Models Using Multi-Modal Wearable Sensors" — uses the BIG IDEAs Lab dataset (publicly available!)
- **Nature Digital Medicine (2025):** "Integration of AI and wearable technology in diabetes management" — comprehensive review supporting the approach

### Regulatory Update
- FDA January 2026 revised general wellness guidance still provides viable path
- Stelo by Dexcom is sold OTC (no prescription) — validates FDA's loosening stance
- Joe's app can position as "wellness awareness" not "medical device" to avoid full FDA clearance

---

## Revised Go-To-Market Strategy

### Phase 1: MVP on Existing Platforms (No Hardware)
- **Tech stack:** React Native + Terra API (pulls Dexcom G7 + Oura Ring 4 data)
- **AI engine:** Claude API for pattern recognition and conversational insights
- Users need: Dexcom G7 (or Stelo) + Oura Ring (or Apple Watch)
- **Key differentiator:** Predict stress-induced glucose events 30-60 minutes before they happen

### Phase 2: Expand to GLP-1/Type 2 Market
- The Oura/Dexcom partnership proves the general metabolic health market is massive
- GLP-1 users (Ozempic, Mounjaro) = tens of millions by 2030
- Position as the "intelligent layer" that predicts glucose responses, not just monitors them

### Phase 3: Caregiver Network
- Partner/family notifications for predicted events
- Built for Keli first → Joe validates → commercial launch

---

## Action Items

1. **Download the BIG IDEAs Lab dataset** (PhysioNet) — free, public, has CGM + wearable data for model training
2. **Test the Oura + Stelo integration** on Keli's setup to understand the UX gap
3. **Terra API evaluation** — confirm it can pull both Dexcom G7 and Oura Ring 4 data simultaneously
4. **Explore Stressomic research** for future direct cortisol sensing integration
5. **Name the app** — suggest brainstorm session with Joe (working title: "GlucoPredict" or keep "Predict, Not Medicate" as tagline)

---

## The Bottom Line

The Oura/Dexcom partnership validates the thesis with a $75M investment but **doesn't execute on the prediction angle**. Nobody is doing what Joe wants to build — stress-based glucose prediction for T1D patients. The academic research is piling up in support. The regulatory path is clearer than ever. The tech stack exists.

The window is open but narrowing — Oura/Dexcom will eventually add predictive features. Joe should move on MVP development in Q2 2026.

---
*Next steps: Download BIG IDEAs dataset, evaluate Terra API, draft app architecture document*